Eli Lilly Joins Race to Develop Coronavirus Treatment
03/17/2020
Pharmaceutical giant Eli Lilly & Co. has entered an agreement to develop an experimental therapy for the new coronavirus with with closely held biotechnology company AbCellera Biologics Inc., according to a Bloomberg report.
The Vancouver-based biotechnology firm is already working on discovering antibodies that could potentially be deployed to stop transmission of the virus and prevent the lung illness known as Covid-19. The co-development agreement was announced by the companies in a statement Thursday afternoon.